# A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Study · id `cardio:ct-nct05643573` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05643573](<https://clinicaltrials.gov/study/NCT05643573>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05643573

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 14830 participants.

## Technical summary

Registry record NCT05643573. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-05 (actual); primary completion 2024-01-31 (actual). Results posted on 2024-12-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 14830 participants (enrolled count; ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Started: 2022-12-05 (actual) (ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Primary completion: 2024-01-31 (actual) (ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Completion: 2024-01-31 (actual) (ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Results first posted: 2024-12-09 (ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Netherlands; Norway; Poland; Portugal; Romania; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05643573, source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05643573-2024-12-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
- Acronym: OCEANIC-AF
- Condition: Prevention of Stroke or Systemic Embolism
- Condition: Atrial Fibrillation
- Intervention (Drug): Asundexian (BAY2433334)
- Intervention (Drug): Apixaban
- Intervention (Drug): Asundexian matching placebo
- Intervention (Drug): Apixaban matching placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Asundexian versus Apixaban in Patients with Atrial Fibrillation (`cardio:pubmed-39225267`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial (`cardio:pubmed-40136309`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a63ef33f041cb93a049ff79e4e6e398ace760bb6e45fd0970071935288f24954
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
